Client Result
Orrick Advises on Redwood Software's Acquisition of Cerberus
February.03.2023
We advised Turn/River Capital on the acquisition by one of its portfolio companies, Redwood Software Inc., of Cerberus, LLC.
Client Result
Orrick Advises Catalyst Biosciences in Reverse Merger with GNI Group
December.28.2022
Orrick advised South San Francisco-based biopharmaceutical company Catalyst Biosciences, Inc. in its acquisition of the F351 program, a ...
Client Result
Orrick Advises Superior Plus on its Acquisition of Low-Carbon Energy Solutions Provider Certarus
December.23.2022
Orrick advised Superior Plus on its acquisition of Certarus in a deal valued at CAD$1.05 billion.
Client Result
Orrick Advises COVA Acquisition on $3.82 Billion SPAC Merger with ECARX
December.20.2022
The merged company will be publicly listed on Nasdaq under the ticker symbol "ECX" with an expected pro forma equity value of approximately $3.82 ...
Client Result
Orrick Advises Getaround on $1.2 Billion SPAC Merger
December.09.2022
Orrick is advising carsharing marketplace Getaround on its definitive agreement to become publicly traded via a SPAC merger with InterPrivate II ...
Client Result
Orrick Advised Arta Finance on $90+ Million Financing Round
November.03.2022
Arta, a digital family office, harnesses AI and machine learning to enable intelligent investing in public market equities and alternative ...
Client Result
Orrick Advises Bayer on Partnership with Ginkgo Bioworks
October.17.2022
Orrick advised Bayer on its three-year strategic partnership with biotech company Ginkgo Bioworks to accelerate the research and development of ...
Client Result
Orrick Advises Equinor on Acquisition of U.S. Battery Storage Developer East Point Energy
July.13.2022
Orrick advised Equinor on an agreement to acquire a 100% stake in the U.S.-based privately owned battery storage developer East Point Energy.
Client Result
Orrick Advises Sonantic on Its Acquisition by Spotify
July.11.2022
Sonantic has built a powerful, AI voice platform that is poised to revolutionize game and film production.
Client Result
Orrick Advises Ipsen on Acquisition of Epizyme
June.27.2022
The primary focus of the acquisition is on the lead medicine, Tazverik® (tazemetostat), a first-in-class, chemotherapy-free EZH2a inhibitor.
Client Result
Orrick Advises Kineta on Merger with Yumanity Therapeutics
June.06.2022
Under the definitive agreement, Kineta will become a wholly-owned subsidiary of Yumanity in an all-stock transaction.
Client Result
Orrick Represents 0x Labs on $70 Million Funding
April.27.2022
Orrick advised 0x Labs, a San Francisco-based open-source decentralized trade platform, on a $70M Series B financing, led by Greylock Partners.
- 1
- 2
- 3 (current)
- 4
- 5